Helsinn Group and Eisai Inc. Announce Start of Phase III Clinical Program of Oral Fixed-Dose Combination of Netupitant/Palonosetron (300 mg/0.50 mg) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)